

## Original Article

## Asian Pacific Journal of Reproduction

Journal homepage: www.apjr.net



doi: 10.4103/2305–0500.311608

## Association between estradiol levels and clinical outcomes of IVF cycles with single blastocyst embryo transfer

Arie A. Polim<sup>1,2,3✉</sup>, Nining Handayani<sup>1,2</sup>, Tri Aprilliana<sup>2</sup>, Roza Silvia<sup>4</sup>, Batara Sirait<sup>1,2,5</sup>, Arief Boediono<sup>1,2,6</sup>, Ivan Sini<sup>1,2</sup><sup>1</sup>Morula IVF Jakarta Clinic, Jakarta, Indonesia<sup>2</sup>IRSI Research and Training Centre, Jakarta, Indonesia<sup>3</sup>Department of Obstetrics and Gynecology, School of Medicine and Health Sciences, Atmajaya Catholic University of Indonesia, Jakarta, Indonesia<sup>4</sup>Morula IVF Padang Clinic, Padang, Indonesia<sup>5</sup>Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Kristen Indonesia, Jakarta, Indonesia<sup>6</sup>Department of Anatomy, Physiology and Pharmacology, IPB University, Bogor, Indonesia

## ABSTRACT

**Objective:** To determine the correlation of different serum estradiol levels on the trigger day with the clinical and laboratory outcomes of *in-vitro* fertilization (IVF) cycles comprising a single fresh top-quality blastocyst transfer.

**Methods:** This was a retrospective observational study performed in Morula IVF Clinic Jakarta. Five hundred forty-two women were recruited and grouped according to their serum estradiol levels on the trigger day of follicular maturation as follows: <2 000 pg/mL, 2 000-2 999 pg/mL, 3 000-3 999 pg/mL, and  $\geq$ 4 000 pg/mL. Clinical pregnancy and miscarriage rates were evaluated as the primary outcomes and embryology laboratory results as the secondary outcomes which consisted of the number of retrieved, mature, and fertilized oocytes, the total sum of derived embryos, and top-quality embryos at cleavage and blastocyst stage.

**Results:** Clinical pregnancy and miscarriage rates did not differ among the groups ( $P>0.05$ ). Nonetheless, the study demonstrated a positive correlation of the serum estradiol levels with the overall laboratory outcomes including the number of retrieved, mature, and fertilized oocytes, the total sum of derived embryos, and top-quality embryos at cleavage and blastocyst stage ( $P<0.001$ ). The subject group with estradiol level of  $\geq$ 4 000 pg/mL was superior to the other groups in its respective median number of retrieved, mature, fertilized oocytes, total derived embryos, and top-quality cleavage- and blastocyst-stage embryos.

**Conclusions:** Although an apparent positive correlation is observed between estradiol levels and laboratory outcomes, serum estradiol level on hCG trigger day is not associated with the clinical outcomes of IVF.

**KEYWORDS:** *In-vitro* fertilization; Estradiol; IVF outcomes; Single blastocyst transfer

## 1. Introduction

In the ovary, estradiol 17- $\beta$  ( $E_2$ ) is a predominant natural potent form of estrogen, which is synthesized through the aromatization of androstenedione upon stimulation by a follicle-stimulating hormone in the granulosa cells. The prominent function of estradiol is to regulate the secretion of gonadotropin through a feedback mechanism. It also plays a pivotal role in folliculogenesis, primarily during the post antral follicular stage[1]. In the proliferative and secretory phase of endometrium, both estradiol and progesterone act as essential regulators of endometrial receptivity[2]. Estrogen induces the proliferation of functional epithelial layers and the expression of progesterone receptors. Through these receptors, progesterone then initiates the conformational and biochemical changes of the epithelium to begin opening the window of implantation during the endometrium mid-secretory phase[3,4].

In an *in-vitro* fertilization (IVF) cycle, a controlled ovarian stimulation treatment stimulates the simultaneous development of multiple follicles in the ovary causing an unavoidable elevation of estradiol. Compared to a natural cycle, the estradiol level during controlled ovarian stimulation might be increased by more than

✉To whom correspondence may be addressed. E-mail: arie.adrianus@atmajaya.ac.id

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

**For reprints contact:** reprints@medknow.com

©2021 Asian Pacific Journal of Reproduction Produced by Wolters Kluwer- Medknow. All rights reserved.

**How to cite this article:** Polim AA, Handayani N, Aprilliana T, Silvia R, Sirait B, Boediono A, et al. Association between estradiol levels and clinical outcomes of IVF cycles with single blastocyst embryo transfer. *Asian Pac J Reprod* 2021; 10(2): 49-55.

**Article history:** Received: 2 October 2020; Revision: 15 December 2020; Accepted: 22 December 2020; Available online: 29 March 2021

ten-fold[5], which resulted in supra-physiologic conditions. Such conditions have raised concern about the plausible effects that elevated estradiol levels have on endometrial receptivity and failed embryo implantation[6].

In attempt to gain a comprehensive understanding of this issue, several molecular investigations and observational studies of IVF practice data have long been conducted. Recently, an analysis of protein profile using Ishikawa cells as an ideal proxy for the *in-vitro* endometrial study revealed that a dose-dependent increase of estradiol-induced the expression of different proteins[7]. However, despite the advancements in the molecular understandings of the deleterious effects of high estradiol concentration, the relationship between elevated estradiol levels and IVF clinical outcomes produces mixed findings[8–12]. Inconsistent findings across several studies have been a matter of debate for over two decades yet a majority of the clinical evidence has relatively shown that the elevation of serum estradiol did not impact the clinical outcomes of IVF[8–10,13,14].

However, as well-discussed by the latest systematic review and meta-analysis conducted by Karatasidou *et al* in 2020[15], one of the main limitations of examining the correlation between levels of estradiol and clinical pregnancy is the discrepancy in the number[8,16] and developmental stage[14,17] of the transferred embryo. This study aimed to clarify the correlation between the different serum estradiol levels and IVF outcomes. Only IVF patients who underwent a fresh single embryo transfer at the blastocyst stage were recruited for this study to ensure an equal probability of pregnancy throughout the different estradiol level study groups.

## 2. Materials and methods

### 2.1. Study population

This study was a retrospective observational design that employed couples who underwent an IVF program with antagonist protocol in Morula IVF Jakarta clinic from January 2016 to December 2018. To reduce confounding factors and guarantee a comparable probability of achieving pregnancy, the inclusion criterion for this study was women who underwent a single fresh embryo transfer of top-quality blastocyst. Patients with uterine pathology (such as myomas, polyp, and adenomyosis), freeze-all cycle, mini-stimulation, and natural cycle were excluded. A total of 542 subjects had met the eligible criteria. The median age of women included in this study was 33 years old, ranging from 22 to 45 years old. The median BMI was 22.80 kg/m<sup>2</sup> with a range of 14.88 kg/m<sup>2</sup> to 41.75 kg/m<sup>2</sup>. Of all subjects, 86.7% (470/542) were diagnosed with primary infertility. The primary causes of infertility were associated with male factors (31.0%) followed by unexplained factors (30.6%), and tubal factors (22.9%).

Top-quality blastocysts were assessed according to Gardner Criteria (degree of blastocoel expansion: 3-5, the combination of inner cell mass and trophoblast score: AA, AB, BA)[18]. To investigate the effects of estradiol dynamic levels on ovulation trigger day, the patients were sorted into 4 groups, *i.e.* group 1 [E<sub>2</sub>: <2 000 pg/mL, (n=190)], group 2 [E<sub>2</sub>: 2 000-2 999 pg/mL, (n=209)], group 3 [E<sub>2</sub>: 3 000-3 999 pg/mL, (n=94)], and group 4 [E<sub>2</sub>: ≥ 4 000 pg/mL, (n=49)]. The primary objective of this study was to evaluate the effects of different estradiol levels on clinical pregnancy and miscarriage rates. The secondary objective was to assess the IVF laboratory outcomes in association with the serum estradiol levels which included the number of retrieved, mature, and fertilized oocytes, number of obtained embryos and number of top-quality embryos at cleavage and blastocyst stage. Complete indexes of subject baseline (age, BMI, type of infertility, infertility causes, infertility duration) and clinical characteristics (hormonal basal levels, hormonal levels on the trigger day, and ovarian stimulation indexes) of each group were presented in Table 1 to provide a comprehensive summary about the studied subject and cycle characteristics.

### 2.2. Ovarian stimulation

All research participants were subjected to controlled ovarian stimulation using antagonist protocol and different forms of gonadotropin products. Administration of gonadotropin [Gonal-F (Merck, Serono), Pergoveris (Merck, Serono), or Menophur (Ferring)] started on day 2/3 of the menstrual cycle. The starting dose was individualized based on the patient's characteristics [age, antral follicle count, anti-Müllerian hormone (AMH) level, and body mass index (BMI)] ranging from 150 IU to 375 IU. Ovarian stimulation response was evaluated after four daily primings of gonadotropin. Subsequent dose alterations were determined by estradiol assays and follicular growth assessments through ultrasonography. A dose of 0.25 mg of Cetrotide (Merck KGaA, Darmstadt, Germany) was primed on day 6/7 of the menstrual cycle. The ovulation trigger, using 6 500 IU of Ovidrel (Merck, Serono), was given when at least three follicles had reached a diameter of ≥18 mm. On that day, serum estradiol and progesterone level were measured. Luteal support [vaginal progesterone: 200 mg Utrogestan® (Besins Healthcare, Belgium)/12 hours and 90 mg Crinone® (Merck, Serono)/day] was administered after ovum pick-up until the human chorionic gonadotropin (hCG) test. In a case of biochemical pregnancy detection (hCG > 50 mIU/mL), patients continued to receive the supporting drugs until the 8th week of pregnancy.

### 2.3. Oocyte retrieval, sperm insemination, and embryo culture

Oocyte retrieval was performed 36 h after follicular maturation trigger injection utilizing transvaginal ultrasound guidance while

patients were under sedation. Intracytoplasmic sperm injection or intracytoplasmic morphologically-selected sperm injection was performed after three hours of cumulus-oocytes complex incubation, followed by embryo culture in a triple gas incubator (37 °C, 5% O<sub>2</sub>, 6% CO<sub>2</sub>) for 5/6 days. A single top-quality blastocyst was transferred into the uterus through trans-abdominal ultrasound guidance.

#### 2.4. Study parameters

Clinical pregnancy was confirmed via ultrasonography or clinical documentation of at least one fetus with a discernible heartbeat. The clinical pregnancy rate was calculated as the number of successful clinical pregnancies divided by the number of subjects performing embryo transfer. Miscarriage was defined as the loss of pregnancy before 20 weeks of gestation. The miscarriage rate was calculated as the number of miscarriage events divided by the number of clinically pregnant subjects[19].

The number of oocytes retrieved was calculated as the median number of total oocytes collected per ovum pick-up procedure. The number of mature oocytes was calculated as the median number of metaphase II oocytes that were viable for intracytoplasmic sperm injection or intracytoplasmic morphologically-selected sperm injection. The number of fertilized oocytes was calculated as the median number of fertilized zygotes after insemination, manifested by two pronuclear. The total number of cleavage (day 3) and blastocyst (day 5/6) stage embryos were calculated as the median number of acquired embryos at the respective developmental stages, regardless of the quality. The number of top-quality cleavage and blastocyst were calculated as the median number of good graded day-3-embryos at the cleavage stage and day-5/6-embryos at the blastocyst stage.

#### 2.5. Statistical analysis

Statistical analysis was performed using Statistical Package for the Social Sciences version 25.0 (SPSS, Inc., Chicago, IL, USA). A minimum of 44 subjects per group was needed to have a statistical power of 90%. A non-parametric test was utilized due to the non-normal data distribution. Multiple analyses using logistic regression were conducted to determine the modification effects of baseline and clinical characteristics variables on the clinical pregnancy and miscarriage outcomes. Confounders were then adjusted to compare the clinical pregnancy rates among the varying estradiol level groups. Beta coefficient adjusted odds ratio, 95% confidence interval of the adjusted odds ratio and *P*-value were calculated. Statistical significance was considered when *P*-value was < 0.05.

#### 2.6. Ethics statement

The study protocol was evaluated and approved by the

Ethics Committee of the Faculty of Medicine University of Indonesia (Ethical approval number: KET-1324/UN2.F1/ETIK/PPM.00.02/2019).

### 3. Results

#### 3.1. Baseline and clinical characteristics

Differences in baseline and clinical characteristics among the study groups that showed statistical significance were median age, basal follicle-stimulating hormone (FSH), basal luteinizing hormone (LH), progesterone level on the trigger day, AMH, antral follicle count, the starting dose of gonadotropin, stimulation duration, total gonadotropin usage, and suppression duration (Table 1). The highest median age was found in group 1 (E<sub>2</sub> <2 000 pg/mL), whereas the lowest age in group 3 (E<sub>2</sub>: 3 000-3 999 pg/mL). Consistent with the highest median age, the highest median total of gonadotropin usage was also observed in group 1.

Almost three-fourths of the patients had a trigger day estradiol level of less than 3 000 pg/mL, which was relatively equally distributed in groups 1 and 2. Group 1 had the lowest median antral follicle count. In this study, antral follicle count was shown to have a positive correlation with the estradiol level. The lowest median basal LH level, trigger day progesterone level, AMH, and the highest basal FSH level were also observed in group 1. Other characteristics including BMI, infertility duration, types of infertility, infertility etiology, basal estradiol, basal progesterone, and endometrial thickness were comparable among the studied groups (Table 1). Overall mild ovarian hyper-stimulation syndrome rate of the study participants was 2.58% (14/542).

#### 3.2. Primary and secondary outcomes

Our study demonstrated that the different estradiol levels did not affect the pregnancy and miscarriage rates (*P*>0.05). As presented in Table 2, no statistically significant differences in the primary outcomes were observed among the groups. Group 1 had the highest pregnancy rate, while group 4 had the lowest. Strikingly, group 1 also presented the highest miscarriage rate. In general, estradiol levels on the trigger day had shown to have no benefit or detrimental effect on the clinical pregnancy (*OR* 0.85, 95% *CI* 0.71-1.03). No important correlation remained unchanged even after adjusting with potential confounders such as age, infertility duration, infertility causes (endometrial factor, PCOS), progesterone on the trigger day, antral follicle count, the starting dose of gonadotropin, total gonadotropin used, and endometrial thickness (Adjusted *OR* 0.82, 95% *CI* 0.68-0.99). A similar trend was also observed in the relationship between estradiol levels on the trigger day and miscarriage (*OR* 0.41, 95% *CI* 0.17-0.99, Adjusted *OR* 0.41, 95% *CI* 0.17-1.00).

**Table 1.** Baseline and clinical characteristics of the study population.

Parameters	Group 1 (n=190)	Group 2 (n=209)	Group 3 (n=94)	Group 4 (n=49)	Z value/ $\chi^2$ value/F value	P-value
<b>Baseline characteristics</b>						
Age (years) <sup>a</sup>	33.50 (6.00)	33.00 (6.00)	31.00 (4.00)	32.00 (5.00)	23.684	<0.001
BMI (kg/m <sup>2</sup> ) <sup>a</sup>	23.20 (5.32)	22.85 (4.37)	22.76 (4.63)	21.52 (5.63)	4.002	0.261
Duration of infertility <sup>a</sup>	5.00 (4.00)	5.00 (5.00)	4.00 (5.00)	5.00 (4.00)	6.401	0.094
Type of infertility <sup>b</sup>						
Primary infertility	159 (83.7%)	184 (88.0%)	81 (86.2%)	46 (93.9%)	4.039	0.257
Secondary infertility	31 (16.3%)	25 (12.0%)	13 (13.8%)	3 (6.1%)		
Etiology of infertility <sup>b</sup>						
Sperm factors	59 (31.1%)	68 (32.5%)	22 (23.4%)	19 (38.8%)	4.151	0.246
Tubal factor	39 (20.5%)	53 (25.4%)	20 (21.3%)	12 (24.5%)	1.533	0.675
Endometrial factor	16 (8.4%)	21 (10.0%)	12 (12.8%)	6 (12.2%)	1.567	0.667
Unexplained	65 (34.2%)	60 (28.7%)	32 (34.0%)	9 (18.4%)	5.493	0.139
Others	22 (11.6%)	25 (12.0%)	18 (19.1%)	6 (12.2%)	3.677	0.299
PCOS	4 (2.1%)	9 (4.3%)	8 (8.5%)	2 (4.1%)	6.355	0.096
<b>Clinical characteristics</b>						
Basal FSH (mIU/mL) <sup>a</sup>	7.42 (3.20)	7.23 (2.50)	6.63 (2.50)	6.31 (2.00)	21.080	<0.001
Basal LH (mIU/mL) <sup>a</sup>	4.23 (2.48)	5.00 (2.65)	5.80 (3.15)	5.55 (2.74)	30.023	<0.001
Basal estradiol (pg/mL) <sup>a</sup>	35.38 (19.06)	34.00 (17.60)	36.00 (17.50)	40.00 (18.87)	2.346	0.504
Basal progesterone (ng/mL) <sup>a</sup>	0.23 (0.24)	0.24 (0.24)	0.29 (0.20)	0.24 (0.23)	6.354	0.096
Progesterone on the trigger day <sup>c</sup>	0.63±0.28	0.71±0.29	0.81±0.31	0.96±0.31	19.233	<0.001
AMH (ng/mL) <sup>a</sup>	1.94 (2.19)	3.40 (2.92)	5.11 (4.65)	5.47 (5.13)	113.415	<0.001
Antral follicle count <sup>a</sup>	9.0 (6.0)	11.0 (7.0)	15.0 (8.0)	15.0 (9.0)	61.175	<0.001
Starting dose of gonadotropin (IU) <sup>a</sup>	225 (150)	225 (150)	225 (150)	225 (150)	9.185	0.027
Stimulation duration (day) <sup>a</sup>	9 (2)	9 (2)	8 (1)	9 (2)	9.910	0.019
Total gonadotropin usage (IU) <sup>a</sup>	2400 (900)	2250 (900)	2025 (1144)	2025 (900)	17.229	0.001
Suppression duration (day) <sup>a</sup>	4.5 (1.0)	4.0 (1.0)	4.0 (1.0)	5 (1.0)	15.272	0.002
Endometrial thickness (mm) <sup>a</sup>	10.50 (2.30)	10.50 (2.40)	11.00 (2.20)	10.85 (2.40)	2.117	0.548

Note: <sup>a</sup>Data are presented as median (IQR), and Kruskal-Wallis tests are used. <sup>b</sup>Data are presented as the number of subjects and percentage [n (%)], and *Chi*-square tests are used for the categorical variable. <sup>c</sup>Data are presented as mean±SD, and analysis of variance tests are used. BMI: body mass index; PCOS: polycystic ovary syndrome; FSH: follicle-stimulating hormone; LH: luteinizing hormone; AMH: anti Müllerian hormone.

**Table 2.** Clinical outcomes of different estradiol level groups [n(%)].

Clinical outcomes	Group 1 (n=190)	Group 2 (n=209)	Group 3 (n=94)	Group 4 (n=49)	P-value
Clinical pregnancy	85 (44.7)	93 (44.5)	36 (38.3)	16 (32.7)	0.340
Miscarriage	10 (11.8)	6 (6.5)	1 (2.8)	0 (0.0)	0.180

Note: *Chi*-square tests are used.

**Table 3.** Embryology laboratory outcomes among the study groups.


Secondary outcomes	Group 1 (n=190)	Group 2 (n=209)	Group 3 (n=94)	Group 4 (n=49)
Number of oocytes retrieved	8 (4)	12 (6) <sup>acd</sup>	15 (8) <sup>ab</sup>	16 (9) <sup>ab</sup>
Number of mature oocytes following ICSI/IMSI	7 (4)	10 (6) <sup>acd</sup>	13 (7) <sup>ab</sup>	15 (7) <sup>ab</sup>
Number of fertilized oocytes	5 (3)	7 (4) <sup>acd</sup>	8 (4) <sup>ab</sup>	11 (7) <sup>ab</sup>
Number of cleavage embryos	5 (4)	7 (4) <sup>acd</sup>	8 (4) <sup>ab</sup>	11 (7) <sup>ab</sup>
Number of top quality cleavage	3 (2)	4 (3) <sup>acd</sup>	5 (3) <sup>ab</sup>	5 (4) <sup>ab</sup>
Number of blastocyst	4 (3)	5 (4) <sup>acd</sup>	6 (3) <sup>ab</sup>	8 (6) <sup>ab</sup>
Number of top quality blastocyst	2 (2)	3 (2) <sup>acd</sup>	3 (2) <sup>ab</sup>	4 (4) <sup>ab</sup>

Note: Data are presented as median (IQR). Kruskal-Wallis variance analysis tests are used to assess more than two independent groups. ICSI: intracytoplasmic sperm injection; IMSI: intracytoplasmic morphologically-selected sperm injection. a: compared with group 1,  $P<0.001$ ; b: compared with group 2,  $P<0.001$ ; c: compared with group 3,  $P<0.001$ ; d: compared with group 4,  $P<0.001$ .

Irrespective of the estradiol levels, the clinical pregnancy rate in the overall studied population was 42.43% (230/542). Evaluation of the receiver operating characteristic curve (ROC curve) was performed to better apprehend the correlation between estradiol levels and pregnancy events. The analysis implied that the estradiol level on trigger day was less adequate to become a predictor of a pregnancy event [area under the curve (AUC) 0.594, 95% CI 0.55 – 0.64] (Figure 1).

On the contrary, laboratory outcomes including the number of

retrieved oocytes, mature oocytes, fertilized oocytes, total and top-quality cleavage-, and blastocyst-stage embryos were shown to positively correlate with the series of estradiol levels ( $P<0.001$ ) (Table 3). Increased serum estradiol concentration on the day of hCG injection was associated with improved yields and achievements in the overall laboratory outcomes. The positive correlation could be explained by the reason of the multiple follicle growth during stimulation, leading to the higher production of estradiol.



**Figure 1.** Receiver operating characteristic (ROC) curve obtained from analyzing the correlation between estradiol level and pregnancy event. Diagonal segments are produced by ties.

#### 4. Discussion

The existing practical data in this study have demonstrated no statistically significant correlation between the estradiol levels on trigger day of follicular maturation and the rate of clinical pregnancy and miscarriage, even after ensuring an equal number of transferred embryo in the study subjects. Our results indicated that estradiol level of  $<3\ 000$  pg/mL was the optimal range for embryo implantation and pregnancy. This finding was similar to the previous studies conducted by Siddharta *et al*[13] and Taskin *et al*[9]. Both studies emphasized the lack of statistical differences in the pregnancy rate or implantation rate among responders exhibiting low and elevated estradiol levels. Moreover, Taskin *et al*[9] have demonstrated a weak correlation between estradiol levels and clinical pregnancy rate through evaluation of area under the curve (AUC 0.532, 95% CI 0.471–0.593)[9]. The result of AUC in our study, likewise, presented a comparatively similar outcome (AUC 0.594, 95% CI 0.55 – 0.64). A large retrospective study of 3 393 fresh IVF cycles in a Chinese population by Wang *et al*[8] has shown that patients who exhibited an elevated estradiol level ( $\geq 3\ 757$  pg/mL) on trigger day seemed to achieve a better clinical pregnancy rate than those with a lower estradiol level ( $<3\ 757$  pg/mL). Moreover, the elevated estradiol level did not increase the risk of adverse perinatal outcomes including preterm birth, low birth weight, and fetal malformation.

Contrary to our findings, in a prospective controlled *in-vitro* study, Valbuena *et al*[12] highlighted the deleterious effects of increasing estradiol levels on both endometrial and embryo development. The study concluded that high estradiol concentration could impair embryo's adhesion phase, causing a lower implantation rate. Supporting those findings, a randomized controlled trial performed

by Shapiro *et al*[20] discovered that the clinical pregnancy rate per frozen embryo transfer was significantly higher compared to the fresh embryo transfer. The authors suggested that the use of exogenous gonadotropins during controlled ovarian stimulation might have contributed to the impaired endometrial receptivity leading to the decreased chance of embryo implantation and pregnancy. Supra-physiologic conditions or elevated estradiol levels due to controlled ovarian stimulation during IVF were also indicated to negatively affect the process of trophoblast invasion and placentation, thus, increasing the risk of pregnancy complications[21].

Several animal model and *in-vitro* studies have also demonstrated the possible negative effect of elevated estradiol levels on the endometrial receptivity for embryo implantation. A 2003 study on mice has demonstrated that the expressions of implantation-related genes such as *Lif*, *Hegfl*, and *Ptsg2* as well as the expressions of genes associated with the preparatory uterine receptive phase (*Ptsg1*, *Areg*) were compromised in response to a high dose estradiol injection[22]. Following that, Zhang and colleagues proposed a novel mechanism about the negative effects of supra-physiological concentration of estradiol in mice, which has led to the over-expression of water-channel genes (*Aqp5/8*) thus giving rise to excessive intra-uterine fluid accumulation. Such a condition could perturb the apposition of an embryo during implantation to the endometrium[23]. A proteomic analysis was also investigated by Ullah and colleagues in 2017. Protein quantification through mass spectrometry utilizing iTRAQ isobaric tags coupled with 2D Nano LC-MS/MS managed to evaluate the physiological impacts of estradiol concentrations on endometrial cells by screening the comparative proteomic profiles of Ishikawa cells pre-treated with different estradiol levels ( $10^{-9}$  M and  $10^{-7}$  M). When the cells were treated with  $10^{-7}$  M estradiol, the expression of 45 proteins were altered in which 43 were up-regulated while 2 proteins were down-regulated[7]. Despite the deleterious effects of high estradiol concentration at a molecular level, our study failed to find such a negative correlation between increased estradiol levels and IVF outcomes.

Our study, particularly, showed a positive correlation between the elevation of estradiol level and the overall laboratory outcomes. In this study, increasing estradiol levels corresponded to the multiple follicular growths induced by gonadotropin stimulation. Therefore, elevated estradiol level is commonly affiliated with an increased number of retrieved oocytes which consequently lead to a higher number of mature oocytes and hence potentially higher derivation of embryos. The previous studies could justify our findings[16]. Through a retrospective review of 128 IVF cycles, positive correlation of the elevated estradiol level was found with the number of retrieved oocytes, and the mean number of viable embryos. While Fatemeh *et al*[16] also indicated a positive correlation between the estradiol level and the clinical pregnancy rate, this study did not. The discrepancy identified was the different number of transferred embryo among



subjects. This study confirmed that by limiting the confounding variables through the recruitment of subjects who proceeded with an equal number of transferred embryo, the positive correlation between estradiol level and pregnancy rate became inconspicuous.

This study also implied that the superior laboratory outcomes which corresponded to the high estradiol level did not improve the clinical pregnancy rate. These results agree with a study by Sunkara *et al*[24] to some extent, in which a non-linear association was identified between the number of retrieved oocytes and the live-birth rate following fresh IVF cycles. In the study, an IVF cycle with around 15 retrieved oocytes culminated in a high live-birth rate. The increased number of retrieved oocytes (>15), however, did not improve the live-birth rate and even exhibited a decline when  $\geq 20$  oocytes were derived. Hence, the theoretical beneficial expectation that a high number of retrieved oocytes has in yielding more good-quality embryos and subsequently improving the pregnancy rate has yet been proven.

Finally, analyzing the clinical outcomes of IVF based upon data of single embryo transfer cycles of the top-quality blastocyst has failed to correlate the estradiol level with the clinical outcomes in the terms of the clinical pregnancy and miscarriage rates. Other aspects such as the human endometrial response are to be taken into consideration as factors responsible for the adverse outcomes in relation to the high estradiol levels on the trigger day or the association to ovarian hyperstimulation syndrome. Further studies are still required to investigate the effect of elevated estradiol levels on the endometrium.

Some limitations have pertained to our study. Firstly, although multiple analysis was conducted to the outcomes of interest, other confounders such as recurrent implantation failure were not calculated. Secondly, this study also lacked to provide prominent indexes of IVF such as pregnancy complications and live-birth outcomes due to the limited availability of such data.

In conclusion, although the overall laboratory outcomes were shown to positively correlate with the estradiol levels, this study did not identify a statistically significant correlation between the different serum estradiol levels on trigger day and the clinical outcomes of IVF.

### Conflict of interest statement

The authors declare that there is no conflict of interest.

### Authors' contributions

Arie Adrianus Polim conceived and designed the study. Nining Handayani and Tri Aprilliana performed data collection and analysis. Arie Adrianus Polim, Nining Handayani, and Tri Aprilliana

interpreted the results. Arie Adrianus Polim, Nining Handayani, Roza Silvia, Batara Sirait, Arief Boediono, and Ivan Sini conducted study literature and drafted the manuscript. All authors have read and approved the final version of the publication.

### References

- [1] Bahr JM. Ovary. In: Skinner MK. (ed.) *Encyclopedia of reproduction*. 2nd ed. Oxford: Academic Press; 2018, p. 1-9.
- [2] Paulson RJ. Hormonal induction of endometrial receptivity. *Fertil Steril* 2011; **96**(3): 530-535.
- [3] Kodaman PH, Taylor HS. Hormonal regulation of implantation. *Obstet Gynecol Clin North Am* 2004; **31**(4): 745-766.
- [4] Simon C, Domínguez F, Valbuena D, Pellicer A. The role of estrogen in uterine receptivity and blastocyst implantation. *Trends Endocrinol Metabol* 2003; **14**(5): 197-199.
- [5] Joo BS, Park SH, An BM, Kim KS, Moon SE, Moon HS. Serum estradiol levels during controlled ovarian hyperstimulation influence the pregnancy outcome of *in vitro* fertilization in a concentration-dependent manner. *Fertil Steril* 2010; **93**(2): 442-446.
- [6] Strowitzki T, Germeyer A, Popovici R, von Wolff M. The human endometrium as a fertility-determining factor. *Hum Reprod Update* 2006; **12**(5): 617-630.
- [7] Ullah K, Rahman TU, Pan HT, Guo MX, Dong XY, Liu J, et al. Serum estradiol levels in controlled ovarian stimulation directly affect the endometrium. *J Mol Endocrinol* 2017; **59**(2): 105-119.
- [8] Wang M, Hao C, Bao H, Huang X, Liu Z, Zhang W, et al. Effect of elevated estradiol levels on the hCG administration day on IVF pregnancy and birth outcomes in the long GnRH-agonist protocol: Analysis of 3 393 cycles. *Arch Gynecol Obstet* 2017; **295**(2): 407-414.
- [9] Taşkin EA, Atabekoglu CS, Musali N, Öztuna D, Sönmezer M. Association of serum estradiol levels on the day of hCG administration with pregnancy rates and embryo scores in fresh ICSI/ET cycles down regulated with either GnRH agonists or GnRH antagonists. *Arch Gynecol Obstet* 2014; **289**(2): 399-405.
- [10] Yoldemir T, Fraser IS. The effect of elevated serum estradiol levels on the day of human chorionic gonadotropin injection on pregnancy outcomes in an assisted reproduction program. *Aust New Zeal J Obstet Gynaecol* 2009; **49**(5): 545-550.
- [11] Simón C, Cano F, Valbuena D, Remohí J, Pellicer A. Implantation: Clinical evidence for a detrimental effect on uterine receptivity of high serum oestradiol concentrations in high and normal responder patients. *Hum Reprod* 1995; **10**(9): 2432-2437.
- [12] Valbuena D, Martín J, De Pablo J, Remohí J, Pellicer A, Simón C. Increasing levels of estradiol are deleterious to embryonic implantation due mainly to a direct effect on the embryo. *Fertil Steril* 2001; **76**(5): 962-968.
- [13] Siddhartha N, Reddy N, Pandurangi M, Tamizharasi M, Radha V, Kanimozhi K. Correlation of serum estradiol level on the day of

- ovulation trigger with the reproductive outcome of intracytoplasmic sperm injection. *J Hum Reprod Sci* 2016; **9**(1): 23-27.
- [14]Chen CH, Zhang X, Barnes R, Confino E, Milad M, Puscheck E, et al. Relationship between peak serum estradiol levels and treatment outcome in *in vitro* fertilization cycles after embryo transfer on day 3 or day 5. *Fertil Steril* 2003; **80**(1): 75-79.
- [15]Karatasidou GI, Bosdou JK, Venetis CA, Zepiridis L, Chatzimeletiou K, Tarlatzi TB, et al. Is the probability of pregnancy after ovarian stimulation for IVF associated with serum estradiol levels on the day of triggering final oocyte maturation with hCG? A systematic review and meta-analysis. *J Assist Reprod Genet* 2020; **37**(7): 1531-1541.
- [16]Feroozanfar F, Moraveji SA, Taghavi SA, Karimi F. Association between serum estradiol level on the day of hCG administration and IVF-ICSI outcome. *J Obstet Gynecol India* 2016; **66**(3): 170-173.
- [17]Imudia AN, Goldman RH, Awonuga AO, Wright DL, Styer AK, Toth TL. The impact of supraphysiologic serum estradiol levels on peri-implantation embryo development and early pregnancy outcome following *in vitro* fertilization cycles. *J Assist Reprod Genet* 2014; **31**(1): 65-71.
- [18]Gardner DK, Lane M, Stevens J, Schlenker T, Schoolcraft WB. Blastocyst score affects implantation and pregnancy outcome: Towards a single blastocyst transfer. *Fertil Steril* 2000; **73**(6): 1155-1158.
- [19]Duffy JMN, Bhattacharya S, Bofill M, Collura B, Curtis C, Evers JLH, et al. Standardizing definitions and reporting guidelines for the infertility core outcome set: An international consensus development study. *Hum Reprod* 2020; **35**(12): 2735-2745.
- [20]Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Hudson C, Thomas S. Evidence of impaired endometrial receptivity after ovarian stimulation for *in vitro* fertilization: A prospective randomized trial comparing fresh and frozen-thawed embryo transfer in normal responders. *Fertil Steril* 2011; **96**(2): 344-348.
- [21]Farhi J, Haroush A Ben, Andrawus N, Pinkas H, Sapir O, Fisch B, et al. High serum oestradiol concentrations in IVF cycles increase the risk of pregnancy complications related to abnormal placentation. *Reprod Biomed Online* 2010; **21**(3): 331-337.
- [22]Ma WG, Song H, Das SK, Paria BC, Dey SK. Estrogen is a critical determinant that specifies the duration of the window of uterine receptivity for implantation. *Proc Natl Acad Sci USA* 2003; **100**(5): 2963-2968.
- [23]Zhang Y, Chen Q, Zhang H, Wang Q, Li R, Jin Y, et al. Aquaporin-dependent excessive intrauterine fluid accumulation is a major contributor in hyper-estrogen induced aberrant embryo implantation. *Cell Res* 2015; **25**(1): 139-142.
- [24]Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A. Association between the number of eggs and live birth in IVF treatment: An analysis of 400 135 treatment cycles. *Hum Reprod* 2011; **26**(7): 1768-1774.